Company Overview and News

 
Sims Metal Management Ltd. (SMSMY) CEO Alistair Field on Q4 2018 Results - Earnings Call Transcript

2018-08-24 seekingalpha
Sims Metal Management Ltd. (OTCPK:SMSMY) Q4 2018 Results Earnings Conference Call August 23, 2018 7:30 PM ET
SMUPF SGM MNTCF SMSMY

 
RPT-Scrap that: China's metal recyclers rush to divert or sell U.S. cargoes as tariffs loom

2018-08-13 reuters
BEIJING, Aug 10 (Reuters) - Chinese copper fabricators and importers are scrambling to divert or resell cargoes of U.S. copper scrap en route to China after Beijing hit such imports with a 25-percent duty as the trade row with Washington deepens, sources said.
SMUPF SGM SMSMY NUE

 
Scrap that: China's metal recyclers rush to divert or sell U.S. cargoes as tariffs loom

2018-08-10 reuters
BEIJING (Reuters) - Chinese copper fabricators and importers are scrambling to divert or resell cargoes of U.S. copper scrap en route to China after Beijing hit such imports with a 25-percent duty as the trade row with Washington deepens, sources said.
SMUPF SGM SMSMY NUE

5
Five Things to Watch for in Australia's August Earnings Season - Bloomberg

2018-07-31 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SGM QRNNF MALRY SETY AMP AZJ SMSMY TTRAF 0035 TLSYY MIN SMUPF GS GLSSP CWLDF CCLAY CCL SREN TWE FRTCF TSRYY JBK GSC CWN TFG AZKHY CCLAF AZNNY GSJ TSRYF OZMLF TLS CWLDY OZL MALRF GJS

26
NZ shares taper off in strong June quarter

2018-06-29 nzherald.co.nz
New Zealand shares ran out of puff in the final day of the June quarter, which has been the strongest quarterly performance in more than two years. Summerset Group Holdings and Ebos Group declined and Westpac Banking Corp gained.
SGM FCREY NZTCF SMSMY ACKDF AUKNY FTRRF KMD SMUPF AOTUF SNZ KMD SML KTHDY AIA FBU WBC SCY SPKKY NZTCY EBOSY SPK WEBNF WBK FRCEF EBO EBOSF AIA WBC FBU EBO

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...